Cytosorbents Corp
CTSO
Get informed when a big investor buys or sells
+ FollowMarket Cap$30.83M
Close$
$2.35
382.2% upside
Current Fair Value
382.2% upsideUndervalued by 382.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $30.83 Million |
|---|---|
| Enterprise Value | $44.98 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.13 |
| Beta | 1.44 |
| Outstanding Shares | 62,738,827 |
Return
| Return on Equity | -540.06% |
|---|---|
| Return on Assets | -29.21% |
| Return on Invested Capital | -57.76% |
Valuation & Multiples
| P/E Ratio | -2.6 |
|---|---|
| PEG | -1.05 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 1.21 |
| Enterprise Value to EBIT | -3.21 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0.42 |
| Debt to Equity | 8.64 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 13, 2026
EPS Estimate
$-0.06
Average shareholder expectationRevenue Estimate
$9.40 M
Average shareholder expectationNext Earnings Call
Expected Date
August 6, 2026
EPS Estimate
$-0.05
Average shareholder expectationRevenue Estimate
$9.38 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 26.47%▼ 0.40% |
|---|---|
| Total Invested | $9.32M▼ 13.50% |
| Investors Holding | 50▼ 1.00% |
ESG Score
No data
About Cytosorbents Corp
CEO: Phillip Chan